Kala Bio Inc Reports Results For The Quarter Ended In December: Earnings Summary

KALA BIO

29/03/2024 13:09

* KALA BIO Inc  KALA.OQ  reported a quarterly adjusted loss
of
$3.18​​ per share for the quarter ended in December, higher than
the same quarter last year, when the company reported EPS of
$-7.97.  The mean expectation of three analysts for the quarter
was for a loss of $3.62 per share. Wall Street expected
results to range from $-4.00 to $-3.08 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * KALA BIO Inc's reported EPS for the quarter was a loss of
$3.18​.
    * The company reported a quarterly loss of $8.63 million.
    * KALA BIO Inc shares had risen by 12.1% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "strong buy"

Wall Street's median 12-month price target for KALA BIO Inc is
$22.00 
This summary was machine generated from LSEG data March 29 at
01:09 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -3.62          -3.18          Beat
 Sep. 30 2023      -2.15          -3.41          Missed
 Jun. 30 2023      -3.19          -4.36          Missed
 Mar. 31 2023      -4.43          -6.99          Missed